One-glance verdict
Overvalued
$74.55 our estimate vs market $115.07
Wall Street consensus: $117.13 (57.1% higher than our fair-value estimate)
54% above our estimate, beyond the bull case
Fundamentals snapshot
Revvity, Inc.
RVTY · NYQ · Healthcare · Diagnostics & Research
Current price
$115.07
52-week range
$81.22 - $118.30
Market cap
$12.84B
Balance sheet
Stretched
3.87x Stretched
Net debt $2.49B. Interest coverage shows how many times profit covers the interest bill.
What stands out
3 Rewards
3 Risks
3 rewards · 3 risks
- Reward Revenue grew 1.6% last year.
- Reward Returns 3.2% on equity, ahead of 33% of its peers.
- Risk Stock trades 49.7% above its 5-year average P/E.
- Risk Operating margin compressed from 22.4% to 12.4% over 3 years.
What this company does
Revvity, Inc.
Revvity provides the essential lab instruments, testing kits, and software that scientists and doctors use to discover new medicines and diagnose diseases. A lot of its business comes from selling the testing supplies that customers must repeatedly buy to use with the machines they purchased, creating a stable income stream for the company. This makes Revvity a key "picks and shovels" supplier that enables the broader healthcare and drug research industries.
How the company got here
Revvity was born out of a major business shift from a long-standing company called PerkinElmer. In 2023, PerkinElmer split into two, selling its applied, food, and enterprise services businesses. The remaining life sciences and diagnostics businesses, which were seen as having higher growth potential, were rebranded as Revvity. This move was designed to create a more focused health sciences company. The name itself comes from combining "revolutionize" and "vita," the Latin word for life.
What it actually does
Revvity provides the tools, technologies, and services that scientists and doctors use to research, develop, and diagnose diseases. Think of them as a crucial supplier to laboratories in pharmaceutical and biotech companies, as well as academic and government research institutions. Their products range from scientific instruments and software to the chemical mixtures (reagents) needed to run tests. For example, they provide the technology used to screen millions of newborn babies for life-threatening diseases every year.
Life Sciences
This is Revvity's largest business segment, making up a little over half of its revenue. It provides instruments, software, and critical ingredients (reagents and antibodies) to researchers in pharmaceutical, biotech, and academic labs. These customers are working on discovering and developing new drugs and therapies. A key part of this segment is helping scientists automate their lab work and analyze complex biological data.
Diagnostics
The Diagnostics part of the company focuses on providing tools and tests for clinical laboratories and healthcare providers to diagnose diseases and health conditions. A major focus is on reproductive health, including screening for newborns and mothers. They also create tests for autoimmune disorders and infectious diseases. This segment aims to provide complete workflows, from the sample to the result, for various medical tests.
What management is betting on now
Revvity's leadership is focused on being a more specialized health sciences company rather than a broad industrial supplier. They are concentrating on high-growth areas like drug discovery and development, particularly in innovative fields like cell and gene therapy. A key part of their strategy is to increase recurring revenue (the predictable income from repeat purchases of supplies and software) instead of relying on one-time equipment sales. To sharpen this focus, the company is divesting (selling off) its lower-margin immunodiagnostics business in China to reallocate those resources to more profitable areas.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$125.57M
FY2024 Q4
$149.78M
FY2025 Q1
$112.17M
FY2025 Q2
$115.45M
FY2025 Q3
$120.00M
FY2025 Q4
$161.79M
FY2026 Q2
$95.45M
Revenue
$711.12M
Net income
$40.72M
Diluted EPS
0.36
Operating cash flow
$115.23M
Free cash flow
$95.45M
Fetching…
Sources
Revenue
$772.06M
Net income
$98.36M
Diluted EPS
0.86
Operating cash flow
$181.96M
Free cash flow
$161.79M
Fetching…
Sources
Revenue
$698.95M
Net income
$46.65M
Diluted EPS
0.40
Operating cash flow
$138.50M
Free cash flow
$120.00M
Fetching…
Sources
Revenue
$720.28M
Net income
$53.95M
Diluted EPS
0.46
Operating cash flow
$134.32M
Free cash flow
$115.45M
Fetching…
Sources
Revenue
$664.76M
Net income
$42.24M
Diluted EPS
0.35
Operating cash flow
$128.16M
Free cash flow
$112.17M
Fetching…
Sources
Revenue
$729.37M
Net income
$94.64M
Diluted EPS
0.77
Operating cash flow
$174.23M
Free cash flow
$149.78M
Fetching…
Sources
Revenue
$684.05M
Net income
$94.37M
Diluted EPS
0.77
Operating cash flow
$147.88M
Free cash flow
$125.57M
Fetching…
Sources
Is it cheap or expensive?
Fair value $74.55 vs current price $115.07
Wall Street consensus is the average analyst price target: $117.13 (57.1% higher than our fair-value estimate).
Our most-likely fair value is $74.55 a share — about 35.2% below today's price of $115.07, so the stock currently looks expensive (overvalued).
Is it drowning in debt?
Stretched
Net debt $2.5B. Interest coverage 3.9x.
Net debt
$2.49B
Interest coverage
3.87x
Revvity, Inc.'s profit covers its interest bill about 3.9 times over. which is weaker than most peers shown here.
Stretched
Worse cushion
Baseline
Better cushion
RVTY
BASELINE
Revvity, Inc.
Total debt $3.35B Interest coverage 3.87x This is the baseline the peer rows are being compared against.
Total debt $290.32M Interest coverage 28.53x +638% vs RVTY Carries about 7.4x more debt cushion than RVTY.
Total debt $1.70B Interest coverage 3.91x +1% vs RVTY Has roughly the same debt cushion as RVTY.
Total debt $1.38B Interest coverage 4.46x +15% vs RVTY Carries about 1.2x more debt cushion than RVTY.
Total debt $1.67B Interest coverage 15.65x +304% vs RVTY Carries about 4.0x more debt cushion than RVTY.
Total debt $5.60B Interest coverage 11.54x +198% vs RVTY Carries about 3.0x more debt cushion than RVTY.
What you should know
The case for and against RVTY
3 Rewards
3 Risks
Rewards
-
Revenue grew 1.6% last year.
-
Returns 3.2% on equity, ahead of 33% of its peers.
-
Free cash flow was positive in 10/10 years.
Risks
-
Stock trades 49.7% above its 5-year average P/E.
-
Operating margin compressed from 22.4% to 12.4% over 3 years.
-
Insider ownership is only 0.4% (peer median: 0.5%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
55.32x
Forward P/E
19.75x
P/B
1.79x
P/S
4.42x
EV/EBITDA
17.59x
PEG ratio
0.71x
Profitability
How much profit each dollar creates
Gross margin
54.3%
Operating margin
12.4%
Net margin
8.3%
ROE
3.2%
ROA
2.3%
Health
Liquidity and balance-sheet strength
Debt / equity
0.47x
Current ratio
1.72x
Quick ratio
1.25x
Total debt
$3.35B
Total cash
$860.32M
Growth
How the business has been compounding
Revenue TTM
$2.90B
Revenue 5Y CAGR
-13.4%
EPS TTM
2.08
EPS 5Y CAGR
-23.3%
Cash flow
How much cash the business throws off
Operating CF TTM
$570.01M
Free CF TTM
$509.41M
FCF margin
17.6%
Dividend
Shareholder payout
Yield
0.2%
Payout ratio
13.5%
Last ex-div date
2026-07-17